Orthofix Medical reported fiscal first quarter 2026 revenue of $196.71 million, surpassing estimates of $194.71 million. Performance varied by segment, with Spine Fixation growing 6%, Therapeutic Solutions growing 5%, and Limb Reconstruction growing 10% on a reported basis. The company issued full-year 2026 guidance on May 21, expecting net sales between $838 million and $848 million and non-GAAP adjusted EBITDA between $90 million and $93 million, while noting it does not expect positive free cash flow for the year. Despite a roughly 22% decline in the stock since the earnings release, analysts' 12-month price target suggests more than 54% upside from current levels.
Orthofix Medical IncRevenue beat and guidance issued, but stock declined 22% and free cash flow not expected positive; analyst target suggests upside.